Amitriptylinoxide
drug drugOn this page
Also known as AmbivalonAmitriptilinoxidoAmitriptyline oxideAmitriptyline-n-oxideAmitriptylinoxydeAmitryptyline-n-oxideEquilibrinJ9.621KSID4253961AMITRIPTYLINE N-OXIDE METABOLITEUS8629135SW-03Amitriptyline N-Oxide
Summary
Amitriptylinoxide (CHEMBL627) is a phase-3 clinical-stage small molecule.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Clinical trials: 2
- Chemistry: 293.4 Da · C20H23NO
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL627 |
| Name | Amitriptylinoxide |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 20313 |
| Molecular formula | C20H23NO |
| Molecular weight | 293.4 |
| InChIKey | ZPMKQFOGINQDAM-UHFFFAOYSA-N |
SMILES: C[N+](C)(CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31)[O-]
IUPAC name: N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine oxide
Also known as: Ambivalon, Amitriptilinoxido, Amitriptyline oxide, Amitriptyline-n-oxide, Amitriptylinoxide, Amitriptylinoxyde, Amitryptyline-n-oxide, Equilibrin, J9.621K, SID4253961, AMITRIPTYLINE N-OXIDE METABOLITE, US8629135
Parent form; salt/anhydrous children: CHEMBL1994889
Patent coverage: 687 distinct patent families (2,433 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,041 (84%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Proto-oncogene tyrosine-protein kinase receptor Ret, Cytochrome P450 1A2, Cytochrome P450 3A4, Cytochrome P450 2C19.
Bioactivity
ChEMBL activities: 7 potent at pChembl ≥ 5 of 7 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| CYP2C19 | 6.4 | Potency | 398.1 | nM | CHEMBL_ACT_4019274 |
| CYP2C19 | 6.4 | AC50 | 398.1 | nM | CHEMBL_ACT_6056945 |
| CYP1A2 | 6.1 | AC50 | 794.3 | nM | CHEMBL_ACT_6003527 |
| CYP3A4 | 5.9 | Potency | 1259 | nM | CHEMBL_ACT_4969714 |
| CYP3A4 | 5.9 | Potency | 1259 | nM | CHEMBL_ACT_5038767 |
| CYP3A4 | 5.9 | AC50 | 1259 | nM | CHEMBL_ACT_6057773 |
| RET | 5 | IC50 | 10000 | nM | CHEMBL_ACT_17622019 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.
Clinical trials
Total trials: 2.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 1 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02237937 | PHASE4 | UNKNOWN | Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene |
| NCT02374567 | PHASE3 | TERMINATED | Pharmacovigilance in Gerontopsychiatric Patients |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.